Dormant cancer cells were cultured under serum-free conditions to induce dormancy and treated with ROCK inhibitor Y-27632 at various time points (early, continuous, and late phases). Cell survival assays measured viability, while immunofluorescence staining for fibronectin visualized matrix assembly. Inhibition of ROCK disrupted fibronectin assembly and cell adhesion, leading to loss of dormant cell survival. Here, FN1 is linked to cancer.